Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
Phase of Trial: Phase I
Latest Information Update: 05 May 2015
Price : $35 *
At a glance
- Drugs Tazarotene (Primary) ; Tazarotene (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Allergan
- 29 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 26 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 20 Aug 2014 New trial record